School of Medicine
Showing 1-10 of 14 Results
James L. Zehnder, M.D.
Professor of Pathology (Research) and of Medicine (Hematology)
Current Research and Scholarly InterestsOur laboratory focuses on translational research in 2 main areas - genomic approaches to diagnosis and minimal residual disease testing for patients with cancer, and molecular basis of disorders of thrombosis and hemostasis. My clinical focus is in molecular pathology, diagnosis and treatment of disorders of hemostasis and thrombosis and general hematology.
Professor (Research) of Psychiatry and Behavioral Sciences (Sleep Medicine)
Current Research and Scholarly InterestsDr. Zeitzer is a circadian physiologist specializing in the understanding of the impact of light on circadian rhythms and other aspects of non-image forming light perception.
He examines the manner in which humans respond to light and ways to manipulate this responsiveness, with direct application to jet lag, shift work, and altered sleep timing in teens. Dr. Zeitzer has also pioneered the use of actigraphy in the determination of epiphenomenal markers of psychiatric disorders.
Bing Melody Zhang
Clinical Associate Professor, Pathology
Current Research and Scholarly InterestsMy main research interests lie in the following areas:
1) Using genetic/genomic approaches to study the genotype-phenotype correlation of inherited non-malignant hematologic disorders, especially platelet disorders.
2) Development and application of molecular assays for clinical testing to support hematopoietic stem cell transplantation and solid organ transplantation.
3) NGS-based TCR/Ig clonality/MRD diagnostic testing.
4) HLA-related disease association and pharmacogenetic testing.
Postdoctoral Scholar, Cardiology
BioDr. Zhang is a Postdoctoral Scholar at RabLab in the cardiopulmonary division. She has a PhD in Pharmacology from University of Rochester, NY. She has research in cardiovascular research and chronobiology published in high impact peer-reviewed journals. She is recipient of honors including predoctoral fellowship from AHA, Travel Grant for Early Career Investigators from Council on Arteriosclerosis, Thrombosis, and Vascular Biology. She has served as ad hoc reviewer for more than 40 manuscripts for reputed journals.
Postdoctoral Scholar, Radiology
BioDr. Moss Zhao is a postdoctoral scholar at Stanford’s Center for Advanced Functional Neuroimaging led by Drs. Greg Zaharchuk and Michael Moseley. He develops cutting-edge and clinically viable imaging technologies to improve the diagnosis and treatment of cerebrovascular diseases across the lifespan. His specific areas of expertise include physiological modeling, arterial spin labeling, Bayesian inference, PET/MRI, and artificial intelligence. His scientific contributions could significantly improve the early detection of strokes and dementia as well as enrich the knowledge of brain development in the first two decades of life.
Dr. Zhao received his DPhil at St Cross College of University of Oxford under the supervision of Prof. Michael Chappell. As an alumni mentor, he supports the career development of students of his alma mater. Since 2016, he has presented his work to more than 3000 delegates at international conferences and held leadership positions in professional societies. His research and teaching are supported by the American Heart Association, the National Institutes of Health, and the European Cooperation in Science and Technology.
Current Research and Scholarly InterestsCurrent Research Focus: molecular targeted theranostic imaging of brain tumor and enhanced drug delivery
Areas of Insterests: molecular imaging, theranostics, fluorescence-guided surgery, brain tumor, drug delivery
Dr. Zhou has made substantial contributions to the growing biomedical research field of Molecular Imaging. Molecular imaging emerged in the mid twentieth century as a highly specialized discipline at the intersection of molecular biology and in vivo imaging, focusing on imaging molecules of medical interest within intact living subjects. Dr. Zhou’s research addresses some of the nation’s most pressing issues related to the development of effective approaches for accurate detection of human diseases and improving their treatment outcome. Her innovations in molecular imaging technology enables the visualization, characterization, and quantification of biologic processes taking place at the cellular and subcellular levels. The multiple and numerous potentialities of Quan’s work are applicable to the diagnosis of diseases such as cancer, neurological and cardiovascular diseases. Her strong education background in biological sciences and biomedical engineering followed by postdoctoral training in translational and clinical research have helped her develop multiple disease-specific molecular probes and imaging strategies for early cancer diagnosis, image-guided surgery, therapeutic delivery prediction and at-risk cardiovascular plaque detection. Her research also contributes to improving the treatment of these disorders by testing and optimizing the execution of new interventions. Her work is expected to have a major economic impact due to earlier disease detection and personalized therapy.
Dr. Zhou’s research has led to emergence of novel solutions and opportunities, in particular, for molecular imaging of cancer and other diseases, for discovering, leveraging and integration of cancer biomarker and tumor microenvironment information, and for novel approaches to acquire real-time high-resolution contrast enhanced visualization of tumor margin and optimization based on imaging depth, quality and speed. Dr. Zhou has been able to formulate the involved clinical and biological problems into biomedical engineering frameworks and find ways to exploit a variety of modern techniques and approaches from photoacoustic imaging, fluorescence-guided surgery, micro-electromechanical systems and therapeutic delivery strategies in developing elegant and effective solutions. Her work in the Neurosurgery Department and Molecular Imaging Program at Stanford involves research related to developing tumor-specific molecular probes, advanced imaging methods and therapeutic delivery systems for adult and pediatric patients with malignant brain cancers to improve margin detection, enhance resection accuracy, and improve treatment outcome.